Triple-Negative Myeloproliferative Neoplasms Vs. Calr, JAK2 or MPL-Mutated Myeloproliferative Neoplasms: Distinct Molecular Characteristics

被引：0
|
作者：
Yun, Jiwon [1 ]
Kim, Jung-Ah [2 ]
Hwang, Byungjin [3 ]
Park, Hee Sue [4 ]
Im, Kyongok [5 ,6 ]
Kim, Sung-Min [7 ]
Jeong, Dajeong [1 ]
Lim, Kyu Min [7 ]
Bang, Duhee [3 ]
Lee, Dong Soon [1 ]
机构：
[1] Seoul Natl Univ Hosp, Dept Lab Med, Seoul, South Korea
[2] Chung Ang Univ Hosp, Dept Lab Med, Seoul, South Korea
[3] Yonsei Univ, Dept Chem, Coll Nat Sci, Seoul, South Korea
[4] Chungbuk Natl Univ Hosp, Dept Lab Med, Seoul, South Korea
[5] Inst Reprod Med, Seoul, South Korea
[6] Populat Med Res Ctr, Seoul, South Korea
[7] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea
来源：
BLOOD | 2018年 / 132卷
关键词：
Myeloproliferative neoplasms; next-generation sequencing; triple negative MPN; chromosome; FISH; telomere;
D O I：
10.1182/blood-2018-99-118013
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1772
引用
收藏
页数：3
相关论文
共 50 条
  • [31] The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?
    Anelli, Luisa
    Zagaria, Antonella
    Specchia, Giorgina
    Albano, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (04)
  • [32] JAK2 mutational status and the contribution of TERT and JAK2 polymorphisms to the occurrence of myeloproliferative neoplasms in Eastern Morocco
    Belmokhtar, Karam Yahya
    Errahhali, Mounia Elidrissi
    Lhousni, Saida
    Errahhali, Manal Elidrissi
    Bouagaga, Rachida
    Ouarzane, Meryem
    Charif, Majida
    Al Attar, Nadia
    Sidqi, Zaina
    Hamaz, Siham
    Bachir, Houda
    Serraj, Khalid Andaloussi
    Boulouiz, Redouane
    Alaoui, Habiba
    Bellaoui, Mohammed
    AFRICAN HEALTH SCIENCES, 2024, 24 (03) : 138 - 146
  • [33] TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients
    Matsuguma, Masafumi
    Yujiri, Toshiaki
    Yamamoto, Kaoru
    Kajimura, Yasuko
    Tokunaga, Yoshihiro
    Tanaka, Mayumi
    Tanaka, Yoshinori
    Nakamura, Yukinori
    Tanizawa, Yukio
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) : 690 - 698
  • [34] The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients
    Zhang, Xinju
    Hu, Tingting
    Wu, Zhiyuan
    Kang, Zhihua
    Liu, Weiwei
    Guan, Ming
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (05) : 611 - 616
  • [35] Case series: patients with JAK2 positive myeloproliferative neoplasms associated with thrombotic events
    Combariza, J. F.
    Olaya, V
    Galvez, K.
    Ballesteros, L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 88 - 88
  • [36] TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients
    Masafumi Matsuguma
    Toshiaki Yujiri
    Kaoru Yamamoto
    Yasuko Kajimura
    Yoshihiro Tokunaga
    Mayumi Tanaka
    Yoshinori Tanaka
    Yukinori Nakamura
    Yukio Tanizawa
    International Journal of Hematology, 2019, 110 : 690 - 698
  • [37] The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients
    Xinju Zhang
    Tingting Hu
    Zhiyuan Wu
    Zhihua Kang
    Weiwei Liu
    Ming Guan
    International Journal of Hematology, 2012, 96 : 611 - 616
  • [38] The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy
    Karantanos, Theodoros
    Moliterno, Alison R.
    BLOOD REVIEWS, 2018, 32 (05) : 426 - 432
  • [39] JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment
    Vannucchi, Alessandro M.
    Pieri, Lisa
    Guglielmelli, Paola
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2011, 2 (01) : 21 - 32
  • [40] JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms
    Maslah, N.
    Roux, B.
    Kaci, N.
    Verger, E.
    De Oliveira, R. Daltro
    Pasquer, H.
    Zhao, L. P.
    Gauthier, N.
    Soret-Dulphy, J.
    Ganesan, S.
    Gou, P.
    Ling, F.
    Parquet, N.
    Vainchenker, W.
    Raffoux, E.
    Padua, R. A.
    Giraudier, S.
    Puissant, A.
    Lobry, C.
    Kiladjian, J. J.
    Cassinat, B.
    Benajiba, L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 11 - 11
12345